8-K Announcements
6Material company update
Apr 2, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Mar 3, 2026·SEC
Roivant Sciences Ltd.(ROIV)Earnings, Financials & Key Ratios
ROIV•NASDAQ
$28.82
$20.91B mkt cap·Price updated May 6, 2026
AboutRoivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.Show more
- Revenue$29M-11.2%
- EBITDA-$989M-121.9%
- Net Income-$172M-104.0%
- EPS (Diluted)-0.24-104.6%
- Gross Margin96.86%+1.8%
- EBITDA Margin-3404.89%-124.6%
- Operating Margin-3453.32%-125.1%
- Net Margin-591.96%-104.5%
- ROE-2.96%-102.7%
- ROIC-50.42%-106.2%
- Debt/Equity0.02-75.1%
ROIV Key Insights
Roivant Sciences Ltd. (ROIV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 87 (top 13%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Good 3Y average ROE of 16.7%
- ✓Share count reduced 12.7% through buybacks
- ✓Healthy 5Y average net margin of 1225.2%
✗Weaknesses
- ✗Negative free cash flow
- ✗Sales declining 15.6% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ROIV Price & Volume
Roivant Sciences Ltd. (ROIV) stock price & volume — 10-year historical chart
Loading chart...
ROIV Growth Metrics
Roivant Sciences Ltd. (ROIV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-15.56%
3 Years-19.3%
TTM-56.36%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-593.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-689.47%
Return on Capital
10 Years-15.2%
5 Years-13.78%
3 Years10.24%
Last Year-16.39%
ROIV Recent Earnings
Roivant Sciences Ltd. (ROIV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 4/12 qtrs (33%)
Q1 2026Latest
Feb 6, 2026EPS
$0.24
Est $0.30
+19.9%
Revenue
$2M
Est $5M
-60.6%
Q4 2025
Nov 10, 2025EPS
$0.28
Est $0.32
+12.4%
Revenue
$2M
Est $6M
-72.0%
Q3 2025
Aug 11, 2025EPS
$0.18
Est $0.25
+27.9%
Revenue
$2M
Est $7M
-70.3%
Q2 2025
May 29, 2025EPS
$0.22
Est $0.26
+16.5%
Revenue
$8M
Est $54M
-86.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 6, 2026 | $0.24vs $0.30+19.9% | $2Mvs $5M-60.6% |
| Q4 2025 | Nov 10, 2025 | $0.28vs $0.32+12.4% | $2Mvs $6M-72.0% |
| Q3 2025 | Aug 11, 2025 | $0.18vs $0.25+27.9% | $2Mvs $7M-70.3% |
| Q2 2025 | May 29, 2025 | $0.22vs $0.26+16.5% | $8Mvs $54M-86.0% |
Based on last 12 quarters of dataView full earnings history →
ROIV Peer Comparison
Roivant Sciences Ltd. (ROIV) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BHVN | 1.06B | 10.04 | -1.46 | -8.66% | 5.36 | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 BMY | 115.43B | 56.54 | 16.39 | -0.22% | 15.01% | 38.96% | 2.55 | |
 PFE | 150.77B | 26.51 | 19.49 | -1.65% | 11.83% | 8.34% | 0.78 | |
 VTRS | 18.37B | 15.95 | -5.32 | -2.98% | -24.58% | -23.89% | 0.98 |
Compare ROIV vs Peers
Roivant Sciences Ltd. (ROIV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ROIV Income Statement
Roivant Sciences Ltd. (ROIV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 67.69M | 23.8M | 55.29M | 61.28M | 32.71M | 29.05M | 13.31M |
| Revenue Growth % | - | -64.85% | 132.34% | 10.84% | -46.62% | -11.19% | -56.36% |
| Cost of Goods Sold | 1.13M | 2.06M | 8.97M | 13.13M | 1.6M | 911K | 1.17M |
| COGS % of Revenue | 1.67% | 8.64% | 16.22% | 21.42% | 4.89% | 3.14% | - |
| Gross Profit | 66.56M▲ 0% | 21.74M▼ 67.3% | 46.32M▲ 113.1% | 48.15M▲ 4.0% | 31.11M▼ 35.4% | 28.14M▼ 9.6% | 12.14M▲ 0% |
| Gross Margin % | 98.33% | 91.36% | 83.78% | 78.58% | 95.11% | 96.86% | 91.21% |
| Gross Profit Growth % | - | -67.34% | 113.08% | 3.96% | -35.38% | -9.55% | - |
| Operating Expenses | 598.98M | 1.09B | 1.4B | 1.22B | -4.47B | 1.03B | 1.23B |
| OpEx % of Revenue | 884.9% | 4591.87% | 2528.6% | 1996.52% | -13651.81% | 3550.19% | - |
| Selling, General & Admin | 335.77M | 259.88M | 775.03M | 600.51M | 416.13M | 591.41M | 599.31M |
| SG&A % of Revenue | 496.04% | 1092.15% | 1401.86% | 979.94% | 1272.07% | 2035.62% | - |
| Research & Development | 263.22M | 236.63M | 483.04M | 525.22M | 439.91M | 550.41M | 628.11M |
| R&D % of Revenue | 388.86% | 994.44% | 873.7% | 857.07% | 1344.75% | 1894.51% | - |
| Other Operating Expenses | 0 | 596.13M | 139.89M | 97.75M | -5.32B | -110.39M | 0 |
| Operating Income | -532.42M▲ 0% | -1.07B▼ 101.1% | -1.35B▼ 26.2% | -1.18B▲ 13.0% | 4.5B▲ 482.6% | -1B▼ 122.3% | -1.22B▲ 0% |
| Operating Margin % | -786.58% | -4500.52% | -2444.82% | -1917.95% | 13746.93% | -3453.32% | -9130.53% |
| Operating Income Growth % | - | -101.14% | -26.22% | 13.05% | 482.62% | -122.31% | - |
| EBITDA | -553.3M | -895.74M | -1.35B | -1.16B | 4.52B | -989.22M | -1.21B |
| EBITDA Margin % | -817.42% | -3764.4% | -2434.09% | -1887.18% | 13814.29% | -3404.89% | -9099.45% |
| EBITDA Growth % | - | -61.89% | -50.23% | 14.06% | 490.77% | -121.89% | -32.58% |
| D&A (Non-Cash Add-back) | -20.88M | 175.16M | 5.93M | 18.86M | 22.04M | 14.07M | 4.14M |
| EBIT | -553.3M | -895.74M | -916.71M | -1.2B | -824.93M | -1.11B | -1.02B |
| Net Interest Income | 10.31M | -1.39M | -6.67M | 4.22M | 111.65M | 258.38M | 191.55M |
| Interest Income | 17.99M | 1.42M | 369K | 32.18M | 146.43M | 258.38M | 191.55M |
| Interest Expense | 7.68M | 2.81M | 7.04M | 27.97M | 34.78M | 0 | 0 |
| Other Income/Expense | -28.56M | 172.35M | 427.89M | -49.52M | 70.82M | 321.7M | 293.54M |
| Pretax Income | -560.99M▲ 0% | -898.55M▼ 60.2% | -923.75M▼ 2.8% | -1.22B▼ 32.6% | 4.57B▲ 472.9% | -681.59M▼ 114.9% | -921.73M▲ 0% |
| Pretax Margin % | -828.77% | -3776.2% | -1670.85% | -1998.75% | 13963.43% | -2346.02% | -6925.09% |
| Income Tax | 7.12M | 1.69M | 369K | 5.19M | 21.5M | 48.17M | 84.3M |
| Effective Tax Rate % | -1.27% | -0.19% | -0.04% | -0.42% | 0.47% | -7.07% | -9.15% |
| Net Income | 1.2B▲ 0% | -809.23M▼ 167.4% | -845.26M▼ 4.5% | -1.01B▼ 19.4% | 4.35B▲ 531.0% | -171.98M▼ 104.0% | -809.24M▲ 0% |
| Net Margin % | 1773.57% | -3400.86% | -1528.89% | -1646.59% | 13294.18% | -591.96% | -6079.94% |
| Net Income Growth % | - | -167.41% | -4.45% | -19.37% | 531% | -103.95% | -593.91% |
| Net Income (Continuing) | -568.11M | -900.23M | -924.12M | -1.23B | 4.55B | -729.76M | -1.01B |
| Discontinued Operations | 1.72B | 0 | 0 | 114.56M | -315.15M | 373.03M | 0 |
| Minority Interest | 76.53M | 264.22M | 404.49M | 449.82M | 479.95M | 499.59M | 704.97M |
| EPS (Diluted) | 1.75▲ 0% | -1.18▼ 167.4% | -1.26▼ 6.8% | -1.42▼ 12.7% | 5.23▲ 468.3% | -0.24▼ 104.6% | -0.00▲ 0% |
| EPS Growth % | - | -167.43% | -6.78% | -12.7% | 468.31% | -104.59% | -689.47% |
| EPS (Basic) | 1.75 | -1.18 | -1.26 | -1.42 | 5.55 | -0.24 | - |
| Diluted Shares Outstanding | 684.79M | 684.79M | 669.75M | 712.79M | 831.05M | 725.4M | 696.86B |
| Basic Shares Outstanding | 684.79M | 684.79M | 669.75M | 712.79M | 783.25M | 725.4M | 696.86B |
| Dividend Payout Ratio | - | - | - | - | 0.14% | - | - |
ROIV Balance Sheet
Roivant Sciences Ltd. (ROIV) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.22B | 2.19B | 2.15B | 1.8B | 6.73B | 5B | 4.66B |
| Cash & Short-Term Investments | 2.19B | 2.13B | 2.06B | 1.68B | 6.54B | 4.89B | 4.53B |
| Cash Only | 2.19B | 2.13B | 2.06B | 1.68B | 6.54B | 2.72B | 1.48B |
| Short-Term Investments | 0 | 0 | 0 | 5.01M | 5.37M | 2.17B | 3.05B |
| Accounts Receivable | 15.28M | 13.83M | 6.73M | 37.64M | 82.81M | 0 | 0 |
| Days Sales Outstanding | 82.39 | 212.17 | 44.44 | 224.22 | 924 | - | - |
| Inventory | 0 | 0 | 0 | 2.76M | 35.25M | 0 | 0 |
| Days Inventory Outstanding | - | - | - | 76.76 | 8.05K | - | - |
| Other Current Assets | 2.14M | 874K | 26.02M | 20.44M | 17.59M | 113.17M | 129.91M |
| Total Non-Current Assets | 257.81M | 502.7M | 438.61M | 591.02M | 490.65M | 436.88M | 565.48M |
| Property, Plant & Equipment | 73.93M | 77.03M | 86.95M | 92.34M | 65.95M | 101.08M | 97.01M |
| Fixed Asset Turnover | 0.92x | 0.31x | 0.64x | 0.66x | 0.50x | 0.29x | 0.13x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 144.88M | 137.84M | 0 | 0 |
| Long-Term Investments | 177.22M | 398.47M | 325.83M | 304.32M | 247.75M | 302.94M | 1.43B |
| Other Non-Current Assets | 6.66M | 27.2M | 25.82M | 49.48M | 39.11M | 32.86M | 126.35M |
| Total Assets | 2.48B▲ 0% | 2.69B▲ 8.6% | 2.59B▼ 3.9% | 2.39B▼ 7.6% | 7.22B▲ 202.2% | 5.44B▼ 24.7% | 5.23B▲ 0% |
| Asset Turnover | 0.03x | 0.01x | 0.02x | 0.03x | 0.00x | 0.01x | 0.00x |
| Asset Growth % | - | 8.58% | -3.89% | -7.56% | 202.25% | -24.72% | -75.47% |
| Total Current Liabilities | 92.12M | 218.96M | 184.37M | 272.45M | 266.76M | 149.41M | 151.96M |
| Accounts Payable | 10.31M | 20.55M | 34.58M | 37.83M | 53.23M | 23.69M | 13.29M |
| Days Payables Outstanding | 3.33K | 3.65K | 1.41K | 1.05K | 12.15K | 9.49K | 4.96K |
| Short-Term Debt | 7.84M | 12.31M | 0 | 40.72M | 12M | 9.84M | 10.44M |
| Deferred Revenue (Current) | 3.62M | 5.92M | 10.15M | 12.44M | 4.17M | 1.17M | 1.17M |
| Other Current Liabilities | 39.74M | 141.42M | 83.98M | 74.84M | 85.94M | 53.93M | 121.07M |
| Current Ratio | 24.09x | 9.99x | 11.64x | 6.60x | 25.24x | 33.47x | 33.47x |
| Quick Ratio | 24.09x | 9.99x | 11.64x | 6.59x | 25.10x | 33.47x | 33.47x |
| Cash Conversion Cycle | - | - | - | -750.81 | -3.18K | - | - |
| Total Non-Current Liabilities | 276.24M | 308.73M | 339.33M | 509.57M | 507.19M | 100.33M | 99.18M |
| Long-Term Debt | 108.59M | 170.28M | 210.03M | 375.51M | 430.59M | 0 | 98.5M |
| Capital Lease Obligations | 64.45M | 62.38M | 62.47M | 53.48M | 47.27M | 90.33M | 368.97M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 103.19M | 76.06M | 53.09M | 80.58M | 29.34M | 10M | -131.69M |
| Total Liabilities | 368.36M | 527.69M | 523.7M | 782.02M | 773.95M | 249.74M | 251.14M |
| Total Debt | 180.88M | 244.98M | 283.89M | 481.4M | 499.75M | 100.17M | 207.44M |
| Net Debt | -2B | -1.89B | -1.78B | -1.2B | -6.04B | -2.62B | -1.27B |
| Debt / Equity | 0.09x | 0.11x | 0.14x | 0.30x | 0.08x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | 0.11x | - | -0.17x |
| Net Debt / EBITDA | - | - | - | - | -1.34x | - | 1.05x |
| Interest Coverage | -69.30x | -381.24x | -191.97x | -42.02x | 129.31x | - | - |
| Total Equity | 2.11B▲ 0% | 2.16B▲ 2.5% | 2.06B▼ 4.7% | 1.61B▼ 22.0% | 6.45B▲ 301.1% | 5.19B▼ 19.6% | 4.97B▲ 0% |
| Equity Growth % | - | 2.53% | -4.65% | -22.02% | 301.13% | -19.56% | -61.9% |
| Book Value per Share | 3.08 | 3.16 | 3.08 | 2.26 | 7.76 | 7.15 | 0.01 |
| Total Shareholders' Equity | 2.03B | 1.9B | 1.66B | 1.16B | 5.97B | 4.69B | 4.27B |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -1.11B | -1.92B | -2.76B | -3.77B | 576.17M | 116.06M | -695M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.35M | 1.45M | -946K | -2.62M | -4.08M | 9.44M | 20.61M |
| Minority Interest | 76.53M | 264.22M | 404.49M | 449.82M | 479.95M | 499.59M | 704.97M |
ROIV Cash Flow Statement
Roivant Sciences Ltd. (ROIV) cash flow — operating, investing & free cash flow history
| Line item | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -761.83M | -552.14M | -677.73M | -843.39M | -765.27M | -839.45M | -839.45M |
| Operating CF Margin % | -1125.49% | -2320.39% | -1225.86% | -1376.29% | -2339.34% | -2889.38% | - |
| Operating CF Growth % | - | 27.52% | -22.75% | -24.44% | 9.26% | -9.69% | -29.49% |
| Net Income | -519.39M | -900.23M | -924.12M | -1.12B | 4.23B | -356.73M | -809.24M |
| Depreciation & Amortization | 0 | 0 | 5.93M | 18.86M | 22.04M | 14.07M | -4.59M |
| Stock-Based Compensation | 0 | 84.96M | 564.96M | 217.78M | 199.63M | 289.03M | 270.66M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -257.73M | 191.2M | -340.22M | 29.09M | -5.24B | -708.77M | -85.43M |
| Working Capital Changes | 15.3M | 71.94M | 15.72M | 6.34M | 19.04M | -77.05M | 13.77M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 6.6M | 3.75M | 15.4M | 4.36M | 22.68M | -18.17M | -12.9M |
| Cash from Investing | 1.69B | -31.7M | 303.3M | -44.27M | 5.2B | -1.77B | 257.62M |
| Capital Expenditures | -4.92M | -5.81M | -17.44M | -12.69M | -1.38M | -4.6M | -7.76M |
| CapEx % of Revenue | 7.26% | 24.4% | 31.54% | 20.71% | 4.22% | 15.83% | - |
| Acquisitions | 1.77B | 0 | -39K | 107.86M | -36.98M | 229.36M | 74.93M |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -20.05M | -25.9M | 600K | -139.43M | 5.24B | 110.47M | 37.16M |
| Cash from Financing | 217.16M | 456.26M | 306.79M | 499.46M | 419.36M | -1.22B | -13.39M |
| Debt Issued (Net) | -32.06M | 0 | 14.81M | 129.75M | -30.7M | -52.75M | 0 |
| Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | 1000K | -1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | -6M | 0 | 0 |
| Share Repurchases | -1.19B | 0 | 0 | 0 | 0 | -1.29B | -503.74M |
| Other Financing | 83.48M | 508K | 291.98M | -10M | 17.51M | 13.41M | -4.3M |
| Net Change in Cash | 1.34B▲ 0% | -127.58M▼ 109.5% | -67.64M▲ 47.0% | -381.92M▼ 464.6% | 4.86B▲ 1372.1% | -3.82B▼ 178.7% | -512.9M▲ 0% |
| Free Cash Flow | -766.75M▲ 0% | -557.94M▲ 27.2% | -695.16M▼ 24.6% | -856.08M▼ 23.1% | -766.65M▲ 10.4% | -844.05M▼ 10.1% | -766.86M▲ 0% |
| FCF Margin % | -1132.75% | -2344.8% | -1257.4% | -1397% | -2343.56% | -2905.21% | -5761.5% |
| FCF Growth % | - | 27.23% | -24.59% | -23.15% | 10.45% | -10.1% | 1.62% |
| FCF per Share | -1.12 | -0.81 | -1.04 | -1.20 | -0.92 | -1.16 | -1.16 |
| FCF Conversion (FCF/Net Income) | -0.63x | 0.68x | 0.80x | 0.84x | -0.18x | 4.88x | 0.95x |
| Interest Paid | 0 | 2.02M | 5.54M | 5.3M | 10.27M | 5.96M | 0 |
| Taxes Paid | 0 | 4.08M | 916K | 5.13M | 12.35M | 61.91M | 0 |
ROIV Key Ratios
Roivant Sciences Ltd. (ROIV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -37.9% | -40.03% | -55% | 107.97% | -2.96% | -16.27% |
| Return on Invested Capital (ROIC) | -424.59% | -362.59% | -252.9% | 817.89% | -50.42% | -50.42% |
| Gross Margin | 91.36% | 83.78% | 78.58% | 95.11% | 96.86% | 91.21% |
| Net Margin | -3400.86% | -1528.89% | -1646.59% | 13294.18% | -591.96% | -6079.94% |
| Debt / Equity | 0.11x | 0.14x | 0.30x | 0.08x | 0.02x | 0.02x |
| Interest Coverage | -381.24x | -191.97x | -42.02x | 129.31x | - | - |
| FCF Conversion | 0.68x | 0.80x | 0.84x | -0.18x | 4.88x | 0.95x |
| Revenue Growth | -64.85% | 132.34% | 10.84% | -46.62% | -11.19% | -56.36% |
ROIV SEC Filings & Documents
Roivant Sciences Ltd. (ROIV) SEC filings — annual & quarterly reports (10-K, 10-Q)
ROIV Frequently Asked Questions
Roivant Sciences Ltd. (ROIV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Roivant Sciences Ltd. (ROIV) reported $13.3M in revenue for fiscal year 2024. This represents a 80% decrease from $67.7M in 2019.
Roivant Sciences Ltd. (ROIV) saw revenue decline by 11.2% over the past year.
Roivant Sciences Ltd. (ROIV) reported a net loss of $809.2M for fiscal year 2024.
Dividend & Returns
Roivant Sciences Ltd. (ROIV) has a return on equity (ROE) of -3.0%. Negative ROE indicates the company is unprofitable.
Roivant Sciences Ltd. (ROIV) had negative free cash flow of $766.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More ROIV
Roivant Sciences Ltd. (ROIV) financial analysis — history, returns, DCA and operating performance tools
Full ROIV Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates